The impact of the new cooperative medical scheme on financial burden of tuberculosis patients: evidence from six counties in China
© Xiang et al. 2016
Received: 22 July 2015
Accepted: 30 December 2015
Published: 28 January 2016
Tuberculosis (TB) patients in China encounter heavy financial burdens throughout the course of their treatment and it is unclear how China’s health insurance systems affect the alleviation of this burden under the integrated approach. This study aimed to measure reimbursement for TB services under the New Cooperative Medical Scheme (NCMS) in rural China and to evaluate changes in catastrophic health expenditure (CHE) caused by the reimbursement policies.
Reimbursement data were obtained from routine data systems for the NCMS in Yichang (YC) and Hanzhong (HZ). 1884 TB inpatients reimbursed by NCMS from 2010 to 2012 were included. Household surveys were conducted. A total of 494 TB patients under the NCMS were selected in this paper. 12 Focus Group Discussions (FGDs) were held. We measured the impact of the NCMS by counterfactual analysis, which analyzed the financial burden alleviation. Equity was assessed by Concentration Index (CI), and disaggregated by project sites.
TB inpatients were reimbursed with an effective reimbursement rate of 57.3 %. Average out-of-pocket (OOP) payments for outpatient and inpatient services after diagnosis were 1413 yuan and 430 yuan, and 3572 yuan and 3013 yuan in YC and HZ, respectively. The reimbursement level for TB outpatient care after diagnosis was very low due to a limited outpatient quota. TB patients in HZ incurred higher effective reimbursement rates, but the incidence of CHE remained higher. The reduction of CHE incidence after the NCMS showed no difference statistically (P > 0.05). The severity of CHE was alleviated slightly. CIs after reimbursement were all below zero and their absolute values were higher than those before reimbursement.
Low reimbursement for TB patients could lead to heavy financial burden. Poor TB patients incurred high rates of CHE. The NCMS was found to be a protective factor for CHE, but the impact was modest and the equity of CHE did not improve. The NCMS reimbursement policies should be improved in the future to include a more comprehensive coverage of care. Supplemental programs may be necessary to expand coverage for TB care.
KeywordsNCMS Impact Financial burden TB
Please see Additional file 1 for translations of the abstract into the six official working languages of the United Nations.
China has the second largest burden of tuberculosis (TB) in the world , and the “directly observed treatment short course” (DOTS) has been implemented by China’s National TB Program to combat this problem. One smear microscopy and one radiography at first visit, and drugs (6 months for new patients, 8 months if previously treated) are provided free of charge. Despite this, TB patients frequently encounter high costs, often through additional medicines, X-rays and laboratory services, during the course of their treatment [2–4]. Within the current TB control program, two main approaches have been employed in China: the TB dispensary approach and the integrated approach . In the TB dispensary approach, TB dispensaries [usually departments of the Center for Diseases Control (CDC)] are in charge of TB case detection, diagnosis, treatment, and case management. TB suspects and patients should be reported and referred to TB dispensaries to confirm diagnoses and for treatment by health workers in general hospitals. Only severe or complicated TB cases are further treated in general hospitals. Since 2000, TB prevention and treatment services have transformed from TB dispensaries to designated hospitals in what is called the integrated approach. This design allows TB dispensaries to provide public health care and general hospitals to offer integrated care to TB patients without referral. Other hospitals, including township hospitals, are responsible for referring suspects and patients to the designated hospitals. The integrated model has been considered the better policy option for future TB health reform in China . Prior studies have shown that TB poses a heavy financial burden on patients, especially on those in rural areas . A systematic review conducted in low- and middle-income countries has shown that cost as a percentage of income was particularly high among poor people . With the considerable strain that TB places on its population, protecting TB patients from financial risk is a priority for Chinese policymakers.
Social protection mechanisms were highlighted in the post-2015 Global TB Strategy put forward by The World Health Organization. Health insurance has been considered as a promising way to protect people from financial catastrophe and impoverishment [9–11]. As for TB control, in the United States, ongoing efforts to control TB were enhanced by bringing millions of currently uninsured Americans into the health care system . Integrating the national TB control program into health insurance schemes is an effective strategy to address challenges in current China . Lack of health insurance is reported to be the key determinant of insufficient TB control in many ways. According to one prospective cohort study, having health insurance helped to improve latent tuberculous infection treatment completion rates in the United States and Canada , while a lack of health insurance was found to be responsible for delay in seeking TB care in China .
In rural China, TB patients are reimbursed by the New Cooperative Medical Scheme (NCMS). There is a growing body of literature that evaluates the impacts of the NCMS programs on health care utilization and economic burden [16–20]; however, they mainly focus on the variation of financial burden on the whole population before and after the NCMS, and few target the impacts of different NCMS reimbursement policies on TB patients specifically. A recent study accessed the effective reimbursement rates of the NCMS among TB patients , but it compared TB patients who lived in counties where their schemes covered costs within TB dispensaries and those who did not. Nonetheless, the alleviation of financial burden among TB patients during the entire course of treatment under the integrated approach remains unknown. Moreover, more indicators are needed to assess the impacts of the NCMS on financial burden.
TB patients have several distinctive features in their demand for health care. First, from the clinical viewpoint, only a small proportion of TB patients require treatment via inpatient services. More commonly, TB patients need repeated, long-term outpatient visits. Second, under the current health care system in China, primary care physicians practicing in local clinics or public health centers often do not have the capacity to treat TB patients due to resource and educational constraints. Rather, TB patients are treated at county- or city-level hospitals based on the national TB control policies in China. While the NCMS may be beneficial to meet the unmet health care needs of those in rural China , under the integrated approach, its impact on alleviating the financial burden on TB patients in rural populations using diversified indexes and whether this impact is consistent with that of the whole population has yet to be unveiled.
This study focused on TB patients in rural areas of central and western China. We measured TB care reimbursement under the NCMS by using data from patient surveys and the NCMS database. We then assessed the impacts of the NCMS on the financial burden of TB patients by counterfactual analysis and discussed whether the NCMS reimbursement policy reached the goal of equity by using the CI.
The national TB epidemiology survey in 2010 revealed that there existed significant differences in the prevalence of active pulmonary TB across different regions in China. The prevalence of active pulmonary TB in the western region was about 1.7 times that in the central region, and 2.4 times that in the eastern region. Moreover, the prevalence of active pulmonary TB in rural areas was about 1.6 times that in urban areas. Hence, this paper focuses on TB care reimbursement in rural areas of central and western China.
The China National Health and Family Planning Commission (NHFPC)-Bill & Melinda Gates Foundation TB Project has been widely conducted in Yichang (YC) and Hanzhong (HZ). The local governments were able and willing to collaborate in this study. The study was therefore conducted in these two cities.
YC is located in the more developed area of central China and had a GDP per capita of 73,947 yuan in 2011. By contrast, HZ is a relatively low-income area located in western China, which had a GDP per capita of 16,935 yuan in 2011. YC and HZ adopted the integrated approach. Therefore, TB dispensaries were responsible for TB control planning, case reporting, drug procurement and distribution, defaults tracing and health education. One county-level general hospital was designated for integrated care within one county.
Three counties (one from each category of high, middle and low GDP per capita) were purposively selected in each city. As a result, we chose six counties as our study settings: Yidu (YD), Zhijiang (ZJ) and Wufeng (WF) in YC and Chenggu (CG), Mianxian (MX) and Zhenba (ZB) in HZ.
Data collection employed a combination of both quantitative and qualitative methods. Quantitative data provided intuitional phenomenon, and qualitative data helped to gain a deeper and more complete understanding of the situation. Quantitative studies included TB patient surveys and reimbursement data from the existing routine data systems for the NCMS. Qualitative studies mainly consisted of a number of Focus Group Discussions (FGDs) and policy documents.
We adopted probability proportional to size (PPS) sampling to select TB patients. Through this process, we planned to obtain 270 cases per city. Thus, 90 cases per county were needed.
First, townships were randomly selected in each county. We planned to select six townships according to the previous TB case registration list. In ZJ, for example, 370 TB cases were registered in 2012. The sampling interval was 61, and the random number was 29. Accordingly, we listed the sampled patients in a table and the sampled townships were chosen.
Second, 15 TB cases – patients who had completed or stopped treatment during 2012 – were selected in each of the six townships from the TB case registration list. If the sample size of the sampled township was not enough, we supplemented it by choosing from a nearby township. If the sample size was still not enough in this situation, we chose patients who registered in the latter half of 2011 and completed the treatment course.
A standardized questionnaire was designed to conduct patient surveys by face-to-face interviews at local dispensaries or designated hospitals. We collected additional information on personal demographic and socio-economic status (such as education, household income/expenditure), TB related diagnostic and treatment pathway, direct health service expenditures, and on the reimbursements from health insurance. The patient survey was conducted by university students from local cities and provinces. These students received training on interview skills and the contents of the questionnaire. Since this paper focuses on patients with health insurance coverage under the NCMS program, we excluded TB patients with other forms of health insurance schemes. As a result, we had 494 patients in our final sample.
In order to understand the medical costs and reimbursements of TB patients, we collected reimbursement data from January 2010 to December 2012 from the existing NCMS routine data system in each of the six counties. Eligible patients were identified via a TB diagnosis code from the information system. The reimbursement data contained information on the patient’s name, sex, age group, choice of health providers, hospitalization costs, and the reimbursement expenses.
In sum, quantitative data were collected from the TB patient database and the NCMS database. These two databases were complementary. On one hand, due to recall bias, TB patients may have exaggerated their medical expenses to highlight their economic burden and they were only able to remember their out-of-pocket (OOP) payments. The NCMS database, however, provided relatively accurate data about total and reimbursement expenses. On the other hand, medical expenditures beyond the NCMS reimbursement packages may have been excluded by the NCMS managers to report higher reimbursement rates for their counties. By comparing expenditures and reimbursement rates with the patient database, we were able to gain more detailed information. For these reasons, the effective reimbursement rates from the patient database were lower than those from medical expense records.
FGDs were held with health care providers from the designated hospitals and TB patients. There were 6 groups each in both YC and HZ. Participants were selected with the help of the local CDCs. One FGD was organized with one stakeholder. The number of participants for each FGD was around 6–8.
The FGDs with the health care providers from the designated hospitals consisted of senior health administrators responsible for public health, heads of TB or infectious disease units, 2–3 chief consultants for TB care, heads of nursing from TB units or wards, and one senior and one junior nurse responsible for TB care. Issues posed included the financing and expenditure of TB care, provision of TB services, TB related health workforce and their income levels, etc.
As for FGDs with patients, inclusion criteria were patients with previous TB treatment experience who could clearly communicate their thoughts. Sex, age group, geographic location of residence, and socio-economic status were considered. Both new and relapsed TB patients were included in the group. Questions regarding their use of and experiences with health care, expenses and reimbursement related to TB care, and their subjective feelings about their financial burden and the usefulness of health insurance were asked.
A total of 12 FGDs were conducted by university faculty members. All FGDs were recorded under the permission of participants. In addition, health insurance policy documents related to the payment and reimbursement of TB treatment as well as provider payment methods were gathered from the study sites.
In our study, total medical expenditure was composed of the actual amount received as reimbursement and any OOP payments. OOP payments were comprised of the expenses below the deductible, the expenses above the deductible which were co-paid by patients and the non-reimbursable amount which were beyond the NCMS benefit packages.
There were two major indicators to empirically measure the reimbursement level: the effective reimbursement rate and the non-reimbursable expenses rate. The effective reimbursement rate was the actual amount received as reimbursement divided by the total medical expenditure . The non-reimbursable expenses rate was the non-reimbursable amount that were beyond the NCMS benefit packages divided by the total medical expenditure.
The definitions mentioned above are consistent with those used by the National Health and Family Planning Commission in China.
It is widely known that there is no commonly accepted criterion for defining CHE . The criteria varies from 10 % of income [25, 26], 10 % of household consumption , to 40 % of disposable income [28, 29]. In this paper we regarded OOP health expenditures in excess of 10 % of annual family income as potentially catastrophic.
Analysis of the financial burden alleviation under the NCMS and the extent to which this resulted in catastrophic expenditure before and after receiving the NCMS reimbursement was also accomplished by counterfactual analysis. The state of the households after receiving reimbursement from the NCMS was factual; the state before households received reimbursement (as if they were not covered by the NCMS) was regarded as a counterfactual situation .
CHEI refers to the incidence of CHE. And CI is the catastrophe index. If a TB patient’s OOP payment as a proportion of their annual income is ≥10 %, then CI = 1; otherwise CI = 0. N is the total number of TB patients in the sample.
AG refers to the average gap of CHE. And P is the proportion of OOP cost as a percentage of the annual income of TB patients who incur CHE. N is the total number of TB patients in the sample.
The difference in CHE incidence and average gap before and after reimbursement reflects the impact of the NCMS.
Where h i represents whether an individual suffers from CHE (yes = 1, no = 0), μ is its mean, and ri = i/N is the fractional rank of income, ranging from 0 to 1. For one individual ranked i, r_i = (i-0.5)/N, in which N is the total number of individuals. In this study, the CI was computed by the R programming language.
We used SPSS 17.0 to conduct the quantitative data analyses. The main analysis focused on the expenditure and reimbursement of TB related services. Chi-square tests were employed to identify differences in effective reimbursement rates between two research cities, and differences in the CHE incidences before and after NCMS reimbursement. P < 0.05 was considered to be statistically significant. Total expenses after diagnosis were analyzed to measure TB care reimbursement under the NCMS. In order to assess impact of the NCMS on TB financial burden alleviation, we used expenses throughout the treatment.
The resulting qualitative data were analyzed using thematic framework analysis . Two researchers independently read through all transcripts and listed recruiting viewpoints relevant to questions in the interview guidelines. Codes were developed based on topic guides and the categories that emerged from the transcripts, and were applied to the data to identify themes. All qualitative data were coded, sorted and classified in terms of the analysis framework. Nvivo10 was used to manage the data. Charting was used to identify common or divergent perceptions and explanations were developed. Analysis was carried out in Chinese to keep information consistent and the final results were translated into English.
Documents concerning health insurance policies were also classified and analyzed by region using thematic framework analysis.
All the data collection instruments, tools and procedures developed for the study were tested in a pilot exercise in one project city. Following this pilot exercise, a workshop was held to discuss any problems that arose and to identify appropriate modifications as required. A logic check of all the data collected was also undertaken to identify data gaps, inaccuracies, and apparent incongruities and inconsistencies.
The patient surveys were conducted by university students from local cities and provinces. These students were trained on interview skills and the contents of the questionnaire. All transcripts were cross-checked by different persons, allowing the identification and correction of any data entry errors.
The NCMS data from ZJ County were partly excluded due to errors in logic and only data from 2012 were included in the analysis.
Ethical permission was obtained from the Institutional Ethics Committee, Chinese Center for Disease Control and Prevention, China.
Demographics of TB patients
Social-economic characteristics of TB patients (n = 494)
Results (% (n))
Age (Mean (SD))
Primary school and lower
Secondary school or at the same level
High school and higher
Salaried job, farming or self-employment
The retired but reemployment
Low (lowest 25)
(Missing = 3)
Middle (medium 50)
High (top 25)
Institutional background: The NCMS program in YC and HZ
Reimbursement by the NCMS for TB outpatient care in 2012
Reimbursement rate or quota
Quota subsidy 200 yuan/year
Quota subsidy 45 yuan/month
70 % of total annual expenditure
Quota subsidy 800 yuan/year
80 % of total annual expenditure
New patient ,2000 yuan/year;
Relapse patient, 2500 yuan/year
Reimbursement by the NCMS for TB inpatient care in 2012
Nominal reimbursement rate (%)
Township health centers
Township health centers
TB care reimbursement under the NCMS
TB inpatient care reimbursement under the NCMS in YC and HZ from 2010 to 2012
Total inpatient expenses (Yuan)
Rate of non- reimbursable expenses (%)
The effective reimbursement rate (%)
TB outpatient and inpatient care reimbursement after diagnosis under the NCMS in YC and HZ from 2010 to 2012
Total Expenses (Yuan)
Total Expenses (Yuan)
“TB patients receive low outpatient reimbursement rates. They prefer to be hospitalized, because they can claim higher reimbursement rates, and it is more comfortable and effective from their point of view. Some patients think, ‘At least I can get a general check-up.’”(Doctors in hospitals, FGDs)
“(The subsidy for doctors is insufficient), we make money by ourselves.” (TB doctors, FGDs)
“They (Doctors) have profit-seeking behavior.” (TB patients, FGDs)
Total outpatient expenses were near 1500 yuan after diagnosis in YC, and it was about 800 yuan in HZ (see Table 5). Outpatient expenses were high in certain counties, particularly in ZJ. The reimbursement level for TB outpatient care after diagnosis was very low. The effective reimbursement rate of TB outpatient care accounted for 5.2 and 48.3 % in YC and HZ, respectively. There were significant differences (P < 0.05) in effective reimbursement rate for outpatient treatment between YC and HZ. TB patients reflected that the reimbursement for TB outpatient care was limited effect.
“The reimbursement for outpatient care was low, and it had no effect. I only got reimbursed for 200 yuan. ” (TB patients, FGDs)
Impact of the NCMS on TB Financial Burden Alleviation
Incidence and average gap of CHE, and concentration index of CHE incidence rate before and after the NCMS reimbursement by county
The CI, our measure of equity, was negative for the NCMS reimbursement in all counties, indicating that in all cases CHE incidence rate was pro-poor. Poorer patients were particularly vulnerable, with high rates of catastrophic spending. But the absolute values of the CI for CHE incidence rate were all below 0.4, suggesting that equity was relatively reasonable. After the NCMS reimbursement, the harsh economic effects of TB on poorer populations were even worse, with the exception of YD.
A review of studies that measured the economic costs of diseases, including TB, showed that low coverage and user charges led to high costs . Pan HQ et al. interviewed 316 patients diagnosed from January 2010 to May 2011 who had already completed their anti-TB treatment in a cross-sectional survey, and found that the average per capita total OOP payment was 3024.0 yuan. They pointed out that the economic burden on patients was still heavy . Long Q et al. found that low income patients paid a total of US$ 149 to 724 (RMB 1241 to 5228) for medical costs for a treatment course . In 2011, the participation rate of NCMS was over 97 % . A majority of TB patients in rural China can be covered by the NCMS, but as a government-subsidized rural health insurance, it mainly focuses on helping cover catastrophic medical expenses . Its impact on the alleviation of the economic burden of TB remains to be seen. By accessing the effective reimbursement rates of the NCMS among TB patients, Wei X et al. found that the NCMS has not relieved the financial burden of TB-related medical costs; however, they focused on the TB dispensary approach.
Overall, our study revealed a mixed picture in terms of TB care reimbursement, and how the NCMS has influenced the level of financial burden and equity of TB patients under the integrated approach. More specifically, the study yielded four major findings.
We found that TB patients paid out of pocket for ancillary services, which were not covered by the NCMS , and revealed that TB outpatient care reimbursement remained inadequate. The quota subsidy for TB outpatient care led to inadequate outpatient reimbursement. Small TB outpatient expenditures may seem to be insignificant, but the annual cumulative amount maybe catastrophic. Yip and her colleagues pointed out that the NCMS does not address a major cause of medical impoverishment: expensive outpatient services for chronic conditions . Disparities between inpatient and outpatient reimbursement policies possibly led to the high hospitalization rates for TB patients. The hospitalization costs were significantly higher, resulting in financial burden for TB patients. Thus, prevention of hospitalizations are needed .
We also found that effective reimbursement rates were far lower than the nominal reimbursement rates for inpatient care. There were three possible explanations for low reimbursement rates for TB inpatient care. First, TB patients had to be hospitalized at medical institutions at the county level or above. In our study, 92.13 % of patients were treated at county hospitals or higher, but reimbursement rules were typically less generous for TB patients hospitalized in higher level facilities. Large deductibles (ranging from 200 yuan to 500 yuan in YC and 300 yuan to 600 yuan in HZ) and high co-payments (ranging from 30 to 50 % in YC and 20 to 40 % in HZ) reduced the proportion of effective reimbursement. As a result, patients had to pay more OOP. Second, TB reimbursement packages were not comprehensive and certain expenses were excluded, including liver protection drugs. Take the medicine reimbursement list of Hubei province as an example – only eleven anti-TB items were included in the NCMS, including streptomycin, isoniazid, rifampicin, ethambutol, sodium aminosalicylate, pyrazinamide, rifapentine and rifamycin. Third, doctors in TB designated hospitals had strong financial incentives for excessive treatment under fee-for-service payment systems, including the use of second-line anti-TB drugs which were expensive and not included in reimbursement schemes. For example, the rate of non-reimbursable expenses accounted for 10.07 % of total medical expenditure in two cities.
The effective reimbursement rate for TB inpatient care has increased over the years, while the OOP payments have not. It appears that most of the reimbursement from the NCMS was offset by the growth of medical expenses , which was consistent with the analysis by Wagstaff et al. who found that the NCMS did not reduce OOP payments per outpatient visit or inpatient spell . Financial burden experienced by TB patients can cause delays, low completion rates, poor adherence and drug resistance, as well as CHE and impoverishment [42, 43].
Reimbursement policy design for TB care led to differences in effective reimbursement rates between regions. Higher nominal reimbursement rates and ceilings for TB inpatient and outpatient care were offered in HZ when compared with YC, as shown in Tables 2 and 3. TB patients in HZ encountered lower medical expenditures and higher effective reimbursement rates, but the incidence and severity of CHE remained higher when compared with YC. This indicates that lower-income TB patients in resource-poor settings bear a heavier financial burden, which is in line with other studies [44, 45].
In YC, the reimbursement level for TB outpatient and inpatient care in ZJ was significantly lower than that in YD and WF, and medical expenses for outpatient and inpatient treatment were much higher. Thus, TB patients in ZJ incurred the highest OOP payments. Though the economic level of ZJ ranked in the middle of the three sample counties in YC, the incidence and severity of CHE remained the most serious. It shows that the main factors associated with the incidence and severity of CHE are medical expenditure and reimbursement level without considering other confounding factors.
TB patients paid a high proportion of medical care expenditure through OOP payments after the NCMS reimbursement. Poor TB patients incurred high rates of catastrophic spending due to inadequate reimbursement, in line with other studies which have found that the occurrence and intensity of CHE was greater among poor inpatients [10, 46, 47]; however, equity remained relatively reasonable. A possible explanation may be that the economically disadvantaged group constrained their essential health demand, which in turn is another avenue for further research.
We found the NCMS to be a protective factor in reducing the severity of CHE in particular, which was consistent with other studies [10, 18]. But the NCMS did not reduce the CHE incidence, with the exception of MX, due to inadequate outpatient and inpatient reimbursement levels, a finding that was in line with previous studies , and only the severity of CHE was relieved.
The equity of CHE incidence has not improved after the implementation of the NCMS. The effective reimbursement rate remains low under the NCMS, and since the program targets reimbursement for overall beneficiaries, equity improvement for TB patients is negatively affected.
Establishing the National Medical Financial Assistance Scheme (MFA) for the poor or disadvantaged may be effective in equity improvement. In 2003, the MFA was implemented in rural areas to assist, among others, poor and near-poor households facing high health care expenses . Although the MFA was established across these six counties, the vast majority of TB patients could not meet the requirements to obtain the assistance services due to the strict admittance conditions.
Our study has its own limitations. First, since it was based on counterfactual analysis, the level of medical expenditures was assumed to be unchanged before and after NCMS reimbursement, while behavioral responses of patients and providers under reimbursement might have changed, which would have led to an increase in health expenditures. Thus, the impact of the NCMS on the alleviation of economic burden might be overestimated. This also reveals the fact that the NCMS has a modest impact on reducing the financial burden experienced by TB patients. Second, YC and HZ are two cities with different social and economic levels. Different reimbursement policies were employed. Thus, in order to eliminate confounding factors, comparisons were only made within each city.
This study examined the impact of the NCMS on TB care reimbursement and its effect on the financial burden of TB patients. A number of conclusions can be drawn from our findings. First, low reimbursement for TB outpatients and inpatients due to low reimbursement quotas led to heavy financial burdens on TB patients. Second, the effective reimbursement rates were lower than the reported nominal reimbursement rates for inpatient care. We also discovered a discrepancy between the lower effective reimbursement rates from the patient database and the higher rates from medical expense records. Third, poorer TB patients incurred higher rates of CHE, leaving lower income patients in a more vulnerable position despite the implementation of the NCMS. Fourth, the NCMS was found to be a protective factor for CHE, but the impact was modest. Furthermore, the equity of CHE did not improve after the NCMS reimbursement.
Our findings are valuable for policymakers to develop more effective interventions to relieve the financial burden of TB patients enrolling in the NCMS. The major policy implications from our study are twofold. First, increasing the reimbursement level for TB outpatients and reducing the variations in the reimbursement level across counties are two important avenues to alleviate the financial burden for TB patients and to increase the equity of health insurance systems. Second, since TB patients need to spend significant amounts of money on non-medical costs as well as on non-reimbursable medical costs during the treatment process, relying on a single policy tool such as health insurance coverage may not completely solve the problem of high financial burdens. A supplemental policy tool such as establishing an MFA program may be necessary to improve equity.
catastrophic health expenditure
focus group discussions
Center of Disease Control and Prevention
directly observed treatment short course
the National Medical Financial Assistance Scheme
New Cooperative Medical Scheme
The study upon which this paper was written is part of the large program entitled “China National Health and Family Planning Commission and the Gates Foundation TB Project” - a collaboration between the Government of China and the Melinda and Bill Gates Foundation (Grant No. 51914), and implemented by the China CDC. The Duke Global Health Institute, USA/Duke Kunshan University in China, and Nanjing Medical University, Huazhong University of Science and Technology and Xi’an Jiaotong University in China were contracted by the Foundation and China CDC to undertake the baseline survey, and monitoring and evaluation of innovative financial models of TB/MDRTB control and care in China. The authors would also like to express their deep appreciation to Prof. Chee-Ruey Hsieh in Global Health Research Center, Duke Kunshan University for his comments on the paper writing, and appreciation to all the staffs, teachers and students participating in the field study.This study was also supported by the project “Research on Economic Risk of Major Diseases and the Protection Effect Model of Rural Residents in the Central and Western Regions of China” (Grant No. 71203068), and the “Study on the Dynamic Optimization of Catastrophic Health Insurance Reimbursement Modes and the Scale of Fund Expenditure in the Perspective of UHC” (Grant No. 71573095), both supported by the National Natural Science Foundation of China.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Wang L, Liu J, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet. 2007;369(9562):691–6. doi:10.1016/S0140-6736(07)60316-X.View ArticlePubMedGoogle Scholar
- Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238. doi:10.1371/journal.pmed.0040238.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhan S, Wang L, Yin A, Blas E. Revenue-driven in TB control—three cases in China. Int J Health Plann Manage. 2004;19(S1):S63–78.View ArticlePubMedGoogle Scholar
- Zhang T, Tang S, Jun G, Whitehead M. Persistent problems of access to appropriate, affordable TB services in rural China: experiences of different socio-economic groups. BMC Public Health. 2007;7:19. doi:10.1186/1471-2458-7-19.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun Q, Yin J, Yin X, Zou G, Liang M, Zhong J, et al. Does the integration of TB medical services in the general hospital improve the quality of TB care? Evidence from a case study in China. J Public Health. 2013;35(2):322–8. doi:10.1093/pubmed/fds089.View ArticleGoogle Scholar
- Wei X, Zou G, Walley J, Yin J, Lonnroth K, Uplekar M, et al. China tuberculosis policy at crucial crossroads: comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PLoS One. 2014;9(3):e90596. doi:10.1371/journal.pone.0090596.PubMed CentralView ArticlePubMedGoogle Scholar
- Pan HQ, Bele S, Feng Y, Qiu SS, Lü JQ, Tang SW, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. Int J Tuberc Lung Dis. 2013;17(12):1575–80. 027–3719.View ArticlePubMedGoogle Scholar
- Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763-75.
- Scheil‐Adlung X, Carrin G, Juetting J, Xu K. What is the impact of social health protection on access to health care, health expenditure and impoverishment? A comparative analysis of three African countries. 2006.Google Scholar
- Zhang L, Cheng X, Tolhurst R, Tang S, Liu X. How effectively can the New Cooperative Medical Scheme reduce catastrophic health expenditure for the poor and non‐poor in rural China? Trop Med Int Health. 2010;15(4):468–75.PubMedGoogle Scholar
- Ekman B. Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country. Health Policy. 2007;83(2):304–13.View ArticlePubMedGoogle Scholar
- Balaban V, Marks SM, Etkind SC, Katz DJ, Higashi J, Flood J, et al. Tuberculosis elimination efforts in the United States in the era of insurance expansion and the Affordable Care Act. Public Health Rep. 2015;130(4):349–54.PubMedGoogle Scholar
- Tang S. Tackling challenges of TB/MDRTB in China: concerted actions are imperative. Infect Dis Poverty. 2015;4:19. doi:10.1186/s40249-015-0050-4.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, et al. Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis. 2015;19(1):31–8. doi:10.5588/ijtld.14.0373.View ArticlePubMedGoogle Scholar
- Li Y, Ehiri J, Tang S, Li D, Bian Y, Lin H, et al. Factors associated with patient, and diagnostic delays in Chinese TB patients: a systematic review and meta-analysis. BMC Med. 2013;11:156. doi:10.1186/1741-7015-11-156.PubMed CentralView ArticlePubMedGoogle Scholar
- Babiarz KS, Miller G, Yi H, Zhang L, Rozelle S. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary health care: multivariate difference-in-difference analysis. Bmj. 2010;341(oct21 2):c5617-c5617.
- Chen Y, Jin GZ. Does health insurance coverage lead to better health and educational outcomes? Evidence from rural China. J Health Econ. 2012;31(1):1–14.View ArticlePubMedGoogle Scholar
- Jing S, Yin A, Shi L, Liu J. Whether New Cooperative Medical Schemes reduce the economic burden of chronic disease in rural China. PLoS One. 2013;8(1):e53062.PubMed CentralView ArticlePubMedGoogle Scholar
- Lei X, Lin W. The new cooperative medical scheme in rural China: does more coverage mean more service and better health? Health Econ. 2009;18(S2):S25–46.View ArticlePubMedGoogle Scholar
- Liu D, Tsegai DW. The New Cooperative Medical Scheme (NCMS) and its implications for access to health care and medical expenditure: evidence from rural China. ZEF-Discussion Papers on Development Policy. 2011(155).
- Wei X, Zou G, Yin J, Walley J, Zhang X, Li R, et al. Effective reimbursement rates of the rural health insurance among uncomplicated tuberculosis patients in China. Trop Med Int Health. 2015;20(3):304–11. doi:10.1111/tmi.12438.View ArticlePubMedGoogle Scholar
- Wagstaff A, Lindelow M, Jun G, Ling X, Juncheng Q. Extending health insurance to the rural population: an impact evaluation of China’s new cooperative medical scheme. J Health Econ. 2009;28(1):1–19.View ArticlePubMedGoogle Scholar
- Yi H, Zhang L, Singer K, Rozelle S, Atlas S. Health insurance and catastrophic illness: a report on the New Cooperative Medical System in rural China. Health Econ. 2009;18 Suppl 2(S2):S119–27. doi:10.1002/hec.1510.View ArticlePubMedGoogle Scholar
- Heeley E, Anderson CS, Huang Y, Jan S, Li Y, Liu M, et al. Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke. 2009;40(6):2149–56.View ArticlePubMedGoogle Scholar
- McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts? Soc Sci Med. 2006;62(4):858–65.View ArticlePubMedGoogle Scholar
- Ranson MK. Reduction of catastrophic health care expenditures by a community-based health insurance scheme in Gujarat, India: current experiences and challenges. Bull World Health Organ. 2002;80(8):613–21.PubMed CentralPubMedGoogle Scholar
- Limwattananon S, Tangcharoensathien V, Prakongsai P. Catastrophic and poverty impacts of health payments: results from national household surveys in Thailand. Bull World Health Organ. 2007;85(8):600–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. The lancet. 2003;362(9378):111–7.View ArticleGoogle Scholar
- Yardim MS, Cilingiroglu N, Yardim N. Catastrophic health expenditure and impoverishment in Turkey. Health Policy. 2010;94(1):26–33.View ArticlePubMedGoogle Scholar
- Sun X, Jackson S, Carmichael G, Sleigh AC. Catastrophic medical payment and financial protection in rural China: evidence from the New Cooperative Medical Scheme in Shandong Province. Health Econ. 2009;18(1):103–19.View ArticlePubMedGoogle Scholar
- Ruhl K. Qualitative Research Practice. A Guide for Social Science Students and Researchers. Journal of Advanced Nursing. 2004;60(6):708.
- Xiao H, Zhangkang Y. The analysis of the implementation of out-patient pooling funds of new Rural Cooperative Medical System in the mid and west area of rural China. Chinese Health Policy Res. 2009;2(5):45–50.Google Scholar
- Liang X, Guo H, Jin C, Peng X, Zhang X. The effect of new cooperative medical scheme on health outcomes and alleviating catastrophic health expenditure in China: a systematic review. PLoS One. 2012;7(8):e40850. doi:10.1371/journal.pone.0040850.PubMed CentralView ArticlePubMedGoogle Scholar
- Barber SL, Yao L. Development and status of health insurance systems in China. Int J Health Plann Manage. 2011;26(4):339–56.View ArticlePubMedGoogle Scholar
- Breman JG, Alilio MS, Mills A, Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. 2004.Google Scholar
- Pan HQ, Bele S, Feng Y, Qiu SS, Lu JQ, Tang SW, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. DiseaseInt J Tuberc Lung Dis. 2013;17(12):1575–80. doi:10.5588/ijtld.13.0144.View ArticleGoogle Scholar
- Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11:393. doi:10.1186/1471-2458-11-393.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang L, Wang ZH, Qian DF, Ni J. Effects of changes in health insurance reimbursement level on outpatient service utilization of rural diabetics: evidence from Jiangsu Province, China. Bmc Health Serv Res. 2014;14. doi:10.1186/1472-6963-14-185.
- Liu Y. China’s public health-care system: facing the challenges. Bull World Health Organ. 2004;82(7):532–8.PubMed CentralPubMedGoogle Scholar
- Liu X, Thomson R, Gong Y, Zhao F, Squire SB, Tolhurst R, et al. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. Trop Med Int Health. 2007;12(12):1464–71.View ArticlePubMedGoogle Scholar
- Taylor Z, Marks S, Rios Burrows N, Weis S, Stricof R, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis. 2000;4(10):931–9.PubMedGoogle Scholar
- Laokri S, Drabo MK, Weil O, Kafando B, Dembele SM, Dujardin B. Patients are paying too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso. PLoS One. 2013;8(2):e56752.PubMed CentralView ArticlePubMedGoogle Scholar
- Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11(1):393.PubMed CentralView ArticlePubMedGoogle Scholar
- Ayé R, Wyss K, Abdualimova H, Saidaliev S. Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan. BMC Public Health. 2010;10(1):18.PubMed CentralView ArticlePubMedGoogle Scholar
- Meng Q, Li R, Cheng G, Blas E. Provision and financial burden of TB services in a financially decentralized system: a case study from Shandong, China. Int J Health Plann Manage. 2004;19(S1):S45–62.View ArticlePubMedGoogle Scholar
- Arsenijevic J, Pavlova M, Groot W. Measuring the catastrophic and impoverishing effect of household health care spending in Serbia. Soc Sci Med. 2013;78:17–25.View ArticlePubMedGoogle Scholar
- Pal R. Measuring incidence of catastrophic out-of-pocket health expenditure: with application to India. Int J Health Care Finance Econ. 2012;12(1):63–85.View ArticlePubMedGoogle Scholar